- ￥500 - 3200
- 卡梅德/KMD Bioscience
- YR1211
- 天津市
- 2025年08月20日
企业认证
相关产品推荐更多 >
科研级Igovomab(伊戈伏单抗) Anti-CA125重组抗体 CA125参照抗体
￥500
科研级Semorinemab(西瑞奈单抗) Anti-MAPT重组抗体 MAPT参照抗体
￥500
科研级Cibisatamab(赛必妥单抗) Anti-CD3E & CEACAM5重组抗体 CD3E & CEACAM5参照抗体
￥1200
科研级Catumaxomab(卡妥索单抗) CD3E & EpCAM参照抗体
￥900科研级Rovelizumab(罗维珠单抗) Anti-ITGAL & CD11a & CD18重组抗体 ITGAL & CD11a & CD18参照抗体
￥500
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体英文名：
Anti-Human B-cell Lymphomas Recombinant Antibody
- 靶点：
B-cell lymphomas[Homo sapiens]
- 浓度：
1mg/ml
- 保质期：
一年
- 抗原来源：
体外表达
- 级别：
科研使用
- 库存：
999
- 供应商：
卡梅德生物科技（天津）有限公司
- 克隆性：
Monoclonal
- 保存条件：
It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
- 形态：
液体/冻干粉
- 亚型：
IgG1
- 规格：
100ug/1mg
| 规格： | 100ug | 产品价格： | ￥500.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥3200.0 |
产品编号：YR1211
产品名称：Anti-Human B-cell Lymphomas Recombinant Antibody
分子名称：Detumomab
产品别称：科研级 Detumomab ( 地莫单抗 ), Anti-B-cell Lymphomas Recombinant Antibody, Research Grade Detumomab
靶点：B-cell lymphomas[Homo sapiens]
抗体亚型：IgG1
克隆性：Monoclonal
来源：CHO Cells
规格：100ug, 200ug, 1mg, 5mg, 10-100mg定制包装
浓度：1mg/ml
纯度：>95% as determined by SDS-PAGE
缓冲体系：PBS, pH7.5
保存条件：It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
运输条件：Shipped on ice packs.
Note：仅供科研使用
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Origin and Pathogenesis of B Cell Lymphomas
. However, errors of these processes are involved in the development of B cell lymphomas. Ig locus-associated translocations of proto-oncogenes are a hallmark of many B cell malignancies. Additional transforming events include inactivating mutations in various tumor
Stereotyped B Cell Receptors in B Cell Leukemias and Lymphomas
Recent research has revealed the existence of subsets (clusters) of patients with different types of B-cell lymphomas and leukemias with restricted, “stereotyped” immunoglobulin (IG) variable heavy complementarity-determining region 3 (VH CDR
Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas
we have followed to analyze the genomic lesions in HIV-related and in other immunodeficiency-related lymphomas, as well in diffuse large B-cell lymphoma (DLBCL) samples derived from immunocompetent hosts. The technology we have used is represented by the GeneChip
技术资料暂无技术资料 索取技术资料
